MedPage Today on MSN

Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief

Trial data suggest a JAK inhibitor beats the leading biologic ...
Seeking Alpha

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
Fierce Biotech

Lynk makes play for the JAK pot with phase 3 rheumatoid arthritis win in China

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...
Seeking Alpha

RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis

NORTH CHICAGO, Ill., June 4, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced that RINVOQ ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older ...
Benzinga.com

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis

The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s (NYSE:ABBV) Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA). GCA is an inflammation of blood vessels, ...

JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
Crain's Chicago Business

Europe poised to OK another use for AbbVie's Rinvoq

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...